-
Reply to Comments on chemoradiotherapy in IDH wild-type/TERT-mutant grade 2/3 glioma
Author: Zhang, Jing; Wang, Peng; Ren, Yin; Chen, Li; Feng, Jin; Liu, Fei; Deng, Kaiwen; Bao, Zhaoshi; Qiu, Xiaoguang; Liu, Yanwei
Journal: CANCER. 2026; Vol. 132, Issue 8, pp. -. DOI: 10.1002/cncr.70359
-
Diagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sampl
Author: Wu, Zhiming; Cao, Lin; Zeng, Jiamin; Feng, Weici; Zhou, Qianghua; Deng, Xinpei; Zhang, Liang; Tan, Xingliang; Wang, Yanjun; Cao, Jiazheng; Xie, Yu; Xu, Abai; Yao, Kai
Journal: CANCER. 2026; Vol. 132, Issue 7, pp. -. DOI: 10.1002/cncr.70373
-
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myelom
Author: Schjesvold, Fredrik; Spencer, Andrew; Cohen, Yael C.; Ocio, Enrique M.; Lopez‐Pardo, Jordi; Cafro, Anna Maria; Callander, Natalie S.; Kaufman, Jonathan L.; Mohan, Meera; Wermke, Martin; Doki, Noriko; Kan, Rebecca; Milanez‐Almeida, Pedro; Stein, Andrew; Trabucco, Gina; Ye, Stan; Kulec, Karolina; Sechaud, Romain; Banerjee, Souvik; Zhong, Huiqin; Lai, Clinton; Rauch, Philipp J.; Raab, Marc S
Journal: CANCER. 2026; Vol. 132, Issue 7, pp. -. DOI: 10.1002/cncr.70341
-
Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotyp
Author: Wang, Jieti; Gu, Yun; Zhang, Ziqiu; Ling, Zhen; Lin, Chao; Liu, Hao; Li, Ruochen; He, Hongyong; Shao, Fei; Xu, Jiejie
Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70363
-
Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical tria
Author: Song, Chunyang; Zhao, Xiaohan; Li, Shuguang; Guo, Xuehan; Zhang, Xueyuan; Wang, Xiaobin; Li, Youmei; Yan, Ke; Su, Jingwei; Xu, Jinrui; Zhu, Shuchai; Shen, Wenbin
Journal: CANCER. 2026; Vol. 132, Issue 6, pp. -. DOI: 10.1002/cncr.70351
-
Long-term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib-based therapie
Author: He, Haiyan; Fu, Qingcheng; Yu, Xuerou; Chen, Xi; Lu, Jing; Jin, Lina; Fan, Xiaoqiang; Du, Juan
Journal: CANCER. 2026; Vol. 132, Issue 4, pp. -. DOI: 10.1002/cncr.70293
-
T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cance
Author: Shan, Yiyang; Ding, Bo; Ji, Feng; Lin, Hao; Shi, Weiwei; Wang, Enxiu; Wang, Chen; Shen, Yang
Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70279
-
The evolution and prognostic impact of HER2-low, HER2-ultralow, and HER2-null status in HER2-negative early breast cancer: A pre- to post-neoadjuvant chemotherapy stud
Author: Qiu, Yibin; Wu, Long; Cai, Weifeng; Chen, Minyan; Jiang, Meichen; Wang, Yali; Liu, Shunyi; He, Peng; Lin, Yuxiang; Chen, Lili; Yang, Yinghong; Wang, Chuan; Zhang, Jie; Fu, Fangmeng
Journal: CANCER. 2026; Vol. 132, Issue 3, pp. -. DOI: 10.1002/cncr.70269
